Pfizer, Summit Therapeutics
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc.
Key Takeaways Summit Therapeutics shares dropped 14% Monday as it reported a fourth-quarter adjusted loss nearly double that ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $61.2 ...
Robert Duggan; Executive Chairman of the Board, Co-Chief Executive Officer; Summit Therapeutics Inc Mahkam Zanganeh; President, Co-Chief Executive Officer, Director; Summit Therapeutics Inc Manmeet ...
Aggregate cash and cash equivalents and short-term investments were $412.3M and $186.2M at December 31, 2024 and December 31, 2023, ...
CIBC Asset Management Inc lifted its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 5.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 21,577 shares of ...
Over the last year, a good number of insiders have significantly increased their holdings in Summit Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback